SecSonar.com

MacroGenics, Inc. (MGNX)

MacroGenics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

MacroGenics, Inc. (MGNX) is a Biotechnology company based in US with a market capitalization of $270.5M. Revenue grew 0.8% year-over-year and free cash flow was negative at -$83M. This page tracks MGNX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 341 employees · IPO Oct 10, 2013

Valuation

Valuation & price

$4.25 · as of May 17, 2026 · -12.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

4.87

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$4.81$3.07$1.33Jul 25Dec 25Jul 26Jul 7, 25$1.36Jul 9, 25$1.59Jul 11, 25$1.61Jul 15, 25$1.49Jul 17, 25$1.54Jul 21, 25$1.47Jul 23, 25$1.81Jul 25, 25$1.71Jul 29, 25$1.58Jul 31, 25$1.56Aug 4, 25$1.64Aug 6, 25$1.61Aug 11, 25$1.47Aug 13, 25$1.66Aug 15, 25$1.58Aug 19, 25$1.49Aug 21, 25$1.44Aug 25, 25$1.64Aug 27, 25$1.72Aug 29, 25$1.77Sep 3, 25$1.91Sep 5, 25$2.00Sep 9, 25$1.73Sep 11, 25$1.65Sep 16, 25$1.47Sep 18, 25$1.73Sep 22, 25$1.73Sep 24, 25$1.72Sep 26, 25$1.73Sep 30, 25$1.68Oct 2, 25$1.71Oct 6, 25$1.76Oct 8, 25$1.78Oct 10, 25$1.69Oct 14, 25$1.61Oct 16, 25$1.69Oct 21, 25$2.02Oct 23, 25$1.83Oct 27, 25$1.91Oct 29, 25$1.69Oct 31, 25$1.66Nov 4, 25$1.45Nov 6, 25$1.36Nov 10, 25$1.43Nov 12, 25$1.47Nov 14, 25$1.50Nov 18, 25$1.54Nov 20, 25$1.37Nov 25, 25$1.45Nov 28, 25$1.53Dec 2, 25$1.42Dec 4, 25$1.38Dec 8, 25$1.33Dec 10, 25$1.40Dec 12, 25$1.40Dec 16, 25$1.35Dec 18, 25$1.57Dec 22, 25$1.59Dec 24, 25$1.62Dec 29, 25$1.60Jan 2, 26$1.61Jan 6, 26$1.70Jan 8, 26$1.79Jan 12, 26$1.79Jan 14, 26$1.78Jan 16, 26$1.72Jan 21, 26$1.74Jan 23, 26$1.80Jan 27, 26$1.84Jan 29, 26$1.93Feb 2, 26$1.75Feb 4, 26$1.73Feb 9, 26$1.80Feb 11, 26$1.72Feb 13, 26$1.71Feb 18, 26$1.70Feb 20, 26$1.70Feb 24, 26$1.73Feb 26, 26$1.98Mar 2, 26$1.94Mar 4, 26$2.08Mar 6, 26$2.23Mar 10, 26$3.43Mar 12, 26$3.12Mar 17, 26$3.08Mar 19, 26$2.90Mar 23, 26$2.92Mar 25, 26$3.17Mar 27, 26$2.93Mar 31, 26$2.89Apr 2, 26$3.07Apr 7, 26$3.35Apr 9, 26$3.44Apr 13, 26$3.47Apr 15, 26$3.52Apr 17, 26$3.46Apr 22, 26$3.42Apr 24, 26$3.19Apr 28, 26$3.01Apr 30, 26$3.08May 4, 26$3.20May 6, 26$3.01May 8, 26$3.00May 12, 26$3.52May 14, 26$4.16May 18, 26$4.35May 20, 26$4.46May 22, 26$4.53May 28, 26$4.21Jun 1, 26$4.14Jun 3, 26$4.20Jun 5, 26$3.91Jun 9, 26$3.91Jun 11, 26$4.01Jun 15, 26$4.13Jun 17, 26$3.96Jun 22, 26$4.58Jun 24, 26$4.78Jun 26, 26$4.81Jul 2, 26$4.71
$1.3352-week range$4.86
Loading valuation history…

Fundamentals

Key fundamentals

$270.5M

Market cap

0.8%

Revenue growth (YoY)

71.1%

Gross margin

-$83M

Free cash flow (USD)

-$83.2M

Net debt

Net cash position

0.8%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$86.6MFY 2017$155.5MFY 2018$60.1MFY 2019$62.0MFY 2020$97.8MFY 2021$75.6MFY 2022$150.0MFY 2023$57.2MFY 2024$148.3MFY 2025$149.5M
$86.6M$149.5M

Free cash flow by year

2016 → 2025

FY 2016$-55.1MFY 2017$-15.0MFY 2018$-178.2MFY 2019$-138.6MFY 2020$-117.8MFY 2021$-150.0MFY 2022$-90.6MFY 2023$-80.0MFY 2024$-72.1MFY 2025$-83.0M
-$55.1M-$83M

Gross margin by year

2021 → 2025

FY 202196.5%FY 202295.1%FY 202385.6%FY 202491.7%FY 202571.1%
96.5%71.1%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsMay 20, 2026Filing
  • Quarterly report10-Q FiledMay 13, 2026Filing
  • 8-K eventEarnings ReleaseMay 13, 2026Filing
  • 8-K eventAsset Purchase AgreementMay 12, 2026Filing
  • 8-K eventRoyalty Purchase Agreement AmendmentMay 4, 2026Filing
  • 8-K eventClinical Hold LiftedApr 8, 2026Filing

Questions

Frequently asked questions

What is MacroGenics, Inc.'s market cap?

MacroGenics, Inc. (MGNX) has a market capitalization of $270.5M.

What is MGNX's P/E ratio?

A meaningful P/E ratio is not available for MGNX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is MGNX's price-to-book (P/B) ratio?

MGNX trades at 4.87 times book value per share.

Are insiders buying MGNX stock?

SEC Form 4 filings show no open-market insider buys at MacroGenics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

ALT

Altimmune, Inc.

$270.9M

TRDA

Entrada Therapeutics, Inc.

$272.5M

AKBA

Akebia Therapeutics, Inc.

$280.3M

IVA

Inventiva S.A.

$259.9M

ACIU

AC Immune S.A.

$281.4M

CDXS

Codexis, Inc.

$258.1M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.